Cytotoxic ribonuclease-based cancer therapies

Drugs of the Future

Volumn 32, Issue 6, 2007, Pages 517-526

  Ramos Nino, Maria E ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGONAUTE 2; CISPLATIN; DICER; DOXORUBICIN; EXORIBONUCLEASE; EXORIBONUCLEASE I; EXORIBONUCLEASE II; GEMCITABINE; MEVINOLIN; OLIGORIBONUCLEASE; PANCREATIC RIBONUCLEASE; POLYRIBONUCLEOTIDE NUCLEOTIDYLTRANSFERASE; RANPIRNASE; RIBONUCLEASE; RIBONUCLEASE A; RIBONUCLEASE H; RIBONUCLEASE II; RIBONUCLEASE III; RIBONUCLEASE L; RIBONUCLEASE P; RIBONUCLEASE PHYM; RIBONUCLEASE R; RIBONUCLEASE T1; RIBONUCLEASE T2; RIBONUCLEASE U2; RIBONUCLEASE V; RIBONUCLEASE V1; TAMOXIFEN; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; VINCRISTINE;

ANAPHYLAXIS; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASTHENIA; BREAST CANCER; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CREATININE CLEARANCE; CYTOTOXICITY; DEEP VEIN THROMBOSIS; DEPRESSION; DRUG DELIVERY SYSTEM; DRUG HYPERSENSITIVITY; DRUG ISOLATION; DRUG MECHANISM; DRUG SPECIFICITY; DRUG WITHDRAWAL; DYSPNEA; ESOPHAGUS CARCINOMA; FATIGUE; HUMAN; HYPOTENSION; KIDNEY CARCINOMA; KIDNEY FAILURE; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PERIPHERAL EDEMA; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; THYMOMA; TREATMENT RESPONSE; UREMIA;

EID: 34547777404     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.06.1110573     Document Type: Review

References (108)

1. D'Alessio, G., Riordan, J. Ribonucleases: Structures and Functions. Academic Press, San Diego, 1997.
2. Leland, P.A., Raines, R.T. Cancer chemotherapy - Ribonucleases to the rescue. Chem Biol 2001, 8(5): 405-13.
3. D'Alessio, G. New and cryptic biological messages from RNases. Trends Cell Biol 1993, 3(4): 106-9.
4. Saxena, S.K., Gravell, M., Wu, Y.N. et al. Inhibition of HIV-1 production and selective degradation of viral RNA by an amphibian ribonuclease. J Biol Chem 1996, 271(34): 20783-8.
5. Tafech, A., Bassett, T., Sparanese, D. et al. Destroying RNA as a therapeutic approach. Curr Med Chem 2006, 13(8): 863-81.
6. Ramos-Nino, M., Mossman, B. Microarray Analysis and RNA Silencing to Determine Genes Functionally Important in Mesothelioma. Cambridge University Press, Cambridge, 2004.
7. Stein, C.A., Cheng, Y.C. Antisense oligonucleotides as therapeutic agents - Is the bullet really magical? Science 1993, 261(5124): 1004-12.
8. Scherer, L.J., Frank, R., Rossi, J.J. Optimization and characterization of tRNA-shRNA expression constructs. Nucleic Acids Res 2007, 35(8): 2620-8.
9. Scherer, L., Rossi, J.J. Therapeutic applications of RNA interference: Recent advances in siRNA design. Adv Genet 2004, 52: 1-21.
10. Matousek, J. Ribonucleases and their antitumor activity. Comp Biochem Physiol C Toxicol Pharmacol 2001, 129(3): 175-91.
11. Ledoux, L. Action of ribonuclease on certain ascites tumours. Nature 1955, 175(4449): 258-9.
12. Ledoux, L. Action of ribonuclease on two solid tumours in vivo. Nature 1955, 176(4470): 36-7.
13. Ledoux, L., Baltus, E. [The effects of ribonuclease on cells of Ehrlich carcinoma.]. Experientia 1954, 10(12): 500-1.
14. Aleksandrowicz, J., Urbanczyk, J., Ostrowska, A. et al. Further research on the activity of ribonucleases in the blood and urine of patients suffering from proliferative hemocytopathia. Blood 1958, 13(7): 652-64.
15. Olson, B.H., Goerner, G.L. Alpha sarcin, a new antitumor agent. I. Isolation, purification, chemical composition, and the identity of a new amino acid. Appl Microbiol 1965, 13: 314-21.
16. Hosokawa, S., Irie, M. Purification and properties of seminal vesicle ribonucleases. J Biochem (Tokyo) 1971, 69(4): 683-97.
17. Dostal, J., Matousek, J. Isolation and some chemical properties of aspermatogenic substance from bull seminal vesicle fluid. J Reprod Fertil 1973, 33(2): 263-74.
18. Matousek, J., Grozdanovic, J. Specific effect of bull seminal ribonuclease (AS RNase) on cell systems in mice. Comp Biochem Physiol A 1973, 46(2): 241-8.
19. D'Alessio, G., Parente, A., Guida, C. et al. Dimeric structure of seminal ribonuclease. FEBS Lett 1972, 27(2): 285-8.
20. Matousek, J. The effect of bovine seminal ribonuclease (AS RNase) on cells of Crocker tumour in mice. Experientia 1973, 29(7): 858-9.
21. Sakakibara, F., Takayanagi, G., Kawauchi, H. et al. An anti-A-like lectin of Rana catesbiana eggs showing unusual reactivity. Biochim Biophys Acta 1976, 444(2): 386-95.
22. Nitta, K., Ozaki, K., Tsukamoto, Y. et al. Characterization of a Rana catesbeiana lectin-resistant mutant of leukemia P388 cells. Cancer Res 1994, 54(4): 928-34.
23. Ardelt, W., Mikulski, S.M., Shogen, K. Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos. Homology to pancreatic ribonucleases. J Biol Chem 1991, 266(1): 245-51.
24. Darzynkiewicz, Z., Carter, M., Mikulski, S. et al. Cytostatic and cytotoxic effects of Pannon (P-30 protein), a novel anticancer agent. Cell Tissue Kinet 1988, 21: 169-82.
25. Ranpirnase: Amphibian ribonuclease A, P-30 protein - Alfacell. Drugs R&D 2007, 8(2): 120-4.
26. Bracale, A., Castaldi, F., Nitsch, L. et al. A role for the intersubunit disulfides of seminal RNase in the mechanism of its antitumor action. Eur J Biochem 2003, 270(9): 1980-7.
27. Di Gaetano, S., D'Alessio, G., Piccoli, R. Second generation antitumour human RNase: Significance of its structural and functional features for the mechanism of antitumour action. Biochem J 2001, 358(Pt. 1):241-7.
28. Kotchetkov, R., Cinatl, J., Krivtchik, A.A. et al. Selective activity of BS-RNase against anaplastic thyroid cancer. Anticancer Res 2001, 21 (2A): 1035-42.
29. Ercole, C., Avitabile, F., Del Vecchio, P. et al. Role of the hinge peptide and the intersubunit interface in the swapping of N-termini in dimeric bovine seminal RNase. Eur J Biochem 2003, 270(23): 4729-35.
30. Russo, A., Antignani, A., Giancola, C. et al. Engineering the refolding pathway and the quaternary structure of seminal ribonuclease by newly introduced disulfide bridges. J Biol Chem 2002, 277(50): 48643-9.
31. Piccoli, R., Tamburrini, M., Plccialll, G. et al. The dual-mode quaternary structure of seminal RNase. Proc Natl Acad Sci USA 1992, 89(5): 1870-4.
32. Avitabile, F., Alfano, C., Spadaccini, R. et al. The swapping of terminal arms in ribonucleases: Comparison of the solution structure of monomeric bovine seminal and pancreatic ribonucleases. Biochemistry 2003, 42(29): 8704-11.
33. Soucek, J., Marinov, I., Benes, J. et al. Immunosuppressive activity of bovine seminal ribonuclease and its mode of action. Immunobiology 1996, 195(3): 271-85.
34. Kim, J.S., Soucek, J., Matousek, J. et al. Mechanism of ribonuclease cytotoxicity. J Biol Chem 1995, 270(52): 31097-102.
35. Monti, D.M., D'Alessio, G. Cytosolic RNase inhibitor only affects RNases with intrinsic cytotoxicity. J Biol Chem 2004, 279(38): 39195-8.
36. Murthy, B.S., Sirdeshmukh, R. Sensitivity of monomeric and dimeric forms of bovine seminal ribonuclease to human placental ribonuclease inhibitor. Biochem J 1992, 281(Pt. 2): 343-8.
37. Haigis, M.C., Kurten, E.L., Raines, R.T. Ribonuclease inhibitor as an intracellular sentry. Nucleic Acids Res 2003, 31(3): 1024-32.
38. Bosch, M., Benito, A., Ribo, M. et al. A nuclear localization sequence endows human pancreatic ribonuclease with cytotoxic activity. Biochemistry 2004, 43(8): 2167-77.
39. Newton, D.L., Xue, Y., Boque, L. et al. Expression and characterization of a cytotoxic human-frog chimeric ribonuclease: Potential for cancer therapy. Protein Eng 1997, 10(4): 463-70.
40. Vescia, S., Tramontano, D., Augusti-Tocco, G. et al. In vitro studies on selective inhibition of tumor cell growth by seminal ribonuclease. Cancer Res 1980, 40(10): 3740-4.
41. Bartholeyns, J., Baudhuin, P. Cytostatic effect and inhibition of protein degradation by dimerized lysozyme: Comparison with the effect of dimerized ribonuclease and reversibility by galactose. Arch Int Physiol Biochim 1979, 87(1): 155-6.
42. Bartholeyns, J., Baudhuin, P. Inhibition of tumor cell proliferation by dimerized ribonuclease. Proc Natl Acad Sci USA 1976, 73(2): 573-6.
43. Di Donato, A., Cafaro, V., D'Alessio, G. Ribonuclease A can be transformed into a dimeric ribonuclease with antitumor activity. J Biol Chem 1994, 269(26): 17394-6.
44. Cafaro, V., De Lorenzo, C., Piccoli, R. et al. The antitumor action of seminal ribonuclease and its quaternary conformations. FEBS Lett 1995, 359(1): 31-4.
45. Kim, J.S., Soucek, J., Matousek, J. et al. Structural basis for the biological activities of bovine seminal ribonuclease. J Biol Chem 1995, 270(18): 10525-30.
46. Kim, J.S., Raines, R.T. A misfolded but active dimer of bovine seminal ribonuclease. Eur J Biochem 1994, 224(1): 109-14.
47. Mastronicola, M.R., Piccoli, R., D'Alessio, G. Key extracellular and intracellular steps in the antitumor action of seminal ribonuclease. Eur J Biochem 1995, 230(1): 242-9.
48. Bracale, A., Spalletti-Cernia, D., Mastronicola, M. et al. Essential stations in the intracellular pathway of cytotoxic bovine seminal ribonuclease. Biochem J 2002, 362(Pt. 3): 553-60.
49. Soucek, J., Pouckova, P., Zadinova, M. et al. Polymer conjugated bovine seminal ribonuclease inhibits growth of solid tumors and development of metastases in mice. Neoplasma 2001, 48(2): 127-32.
50. Kim, J.S., Raines, R.T. Bovine seminal ribonuclease produced from a synthetic gene. J Biol Chem 1993, 268(23): 17392-6.
51. Cinatl, J. Jr., Cinatl, J., Kotchetkov, R. et al. Bovine seminal ribonuclease selectively kills human multidrug-resistant neuroblastoma cells via induction of apoptosis. Int J Oncol 1999, 15(5): 1001-9.
52. Spalletti-Cernia, D., Sorrentino, R., Di Gaetano, S. et al. Antineoplastic ribonucleases selectively kill thyroid carcinoma cells via caspase-mediated induction of apoptosis. J Clin Endocrinol Metab 2003, 88(6): 2900-7.
53. Mosimann, S.C., Ardelt, W., James, M.N. Refined 1.7 A X-ray crystallographic structure of P-30 protein, an amphibian ribonuclease with anti-tumor activity. J Mol Biol 1994, 236(4): 1141-53.
54. Notomista, E., Catanzano, F., Graziano, G. et al. Onconase: An unusually stable protein. Biochemistry 2000, 39(30): 8711-8.
55. Leland, P.A., Staniszewski, K.E., Kim, B. et al. A synapomorphic disulfide bond is critical for the conformational stability and cytotoxicity of an amphibian ribonuclease. FEBS Lett 2000, 477(3): 203-7.
56. Ribo, M., Bosch, M., Torrent, G. et al. Quantitative analysis, using MALDI-TOF mass spectrometry, of the N-terminal hydrolysis and cyclization reactions of the activation process of Onconase. Eur J Biochem 2004, 271(6): 1163-71.
57. Boix, E., Wu, Y., Vasandani, V.M. et al. Role of the N terminus in RNase A homologues: Differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity. J Mol Biol 1996, 257(5): 992-1007.
58. Irie, M., Nitta, K., Nonaka, T. Biochemistry of frog ribonucleases. Cell Mol Life Sci 1998, 54(8): 775-84.
59. Titani, K., Takio, K., Kuwada, M. et al. Amino acid sequence of sialic acid binding lectin from frog (Rana catesbeiana) eggs. Biochemistry 1987, 26(8): 2189-94.
60. Kamiya, Y., Oyama, F., Oyama, R. et al. Amino acid sequence of a lectin from Japanese frog (Rana japonica) eggs. J Biochem (Tokyo) 1990, 108(1): 139-43.
61. Saxena, S.K., Sirdeshmukh, R., Ardelt, W. et al. Entry into cells and selective degradation of tRNAs by a cytotoxic member of the RNase A family. J Biol Chem 2002, 277(17): 15142-6.
62. Leland, P.A., Schultz, L.W., Kim, B.M. et al. Ribonuclease A variants with potent cytotoxic activity. Proc Natl Acad Sci USA 1998, 95(18): 10407-12.
63. Leland, P.A., Staniszewski, K.E., Kim, B.M. et al. Endowing human pancreatic ribonuclease with toxicity for cancer cells. J Biol Chem 2001, 276(46): 43095-102.
64. Lee, J.E., Raines, R.T. Contribution of active-site residues to the function of Onconase, a ribonuclease with antitumoral activity. Biochemistry 2003, 42(39): 11443-50.
65. Notomista, E., Catanzano, F., Graziano, G. et al. Contribution of chain termini to the conformational stability and biological activity of Onconase. Biochemistry 2001, 40(31): 9097-103.
66. Liao, Y.D., Wang, S.C., Leu, Y.J. et al. The structural integrity exerted by N-terminal pyroglutamate is crucial for the cytotoxicity of frog ribonuclease from Rana pipiens. Nucleic Acids Res 2003, 31(18): 5247-55.
67. Arnold, U., Schulenburg, C., Schmidt, D. et al. Contribution of structural peculiarities of Onconase to its high stability and folding kinetics. Biochemistry 2006, 45(11): 3580-7.
68. Bretscher, L.E., Abel, R.L., Raines, R.T. A ribonuclease A variant with low catalytic activity but high cytotoxicity. J Biol Chem 2000, 275(14): 9893-6.
69. Haigis, M.C., Raines, R.T. Secretory ribonucleases are internalized by a dynamin-independent endocytic pathway. J Cell Sci 2003, 116(Pt. 2): 313-24.
70. Wu, Y., Mikulski, S.M., Ardelt, W. et al. A cytotoxic ribonuclease. Study of the mechanism of Onconase cytotoxicity. J Biol Chem 1993, 268(14): 10686-93.
71. Wu, Y., Saxena, S.K., Ardelt, W. et al. A study of the intracellular routing of cytotoxic ribonucleases. J Biol Chem 1995, 270(29): 17476-81.
72. Sakakibara, F., Kawauchi, H., Takayanagi, G. et al. Egg lectin of Rana japonica and its receptor glycoprotein of Ehrlich tumor cells. Cancer Res 1979, 39(4): 1347-52.
73. Nitta, K., Takayanagi, G., Kawauchi, H. et al. Isolation and characterization of Rana catesbeiana lectin and demonstration of the lectin-binding glycoprotein of rodent and human tumor cell membranes. Cancer Res 1987, 47(18): 4877-83.
74. Okabe, Y., Katayama, N., Iwama, M. et al. Comparative base specificity, stability, and lectin activity of two lectins from eggs of Rana catesbeiana and R. japonica and liver ribonuclease from R. catesbeiana. J Biochem (Tokyo) 1991, 109(5): 786-90.
75. Saxena, S.K., Rybak, S.M., Winkler, G. et al. Comparison of RNases and toxins upon injection into Xenopus oocytes. J Biol Chem 1991, 266(31): 21208-14.
76. Rodriguez, M., Torrent, G., Bosch, M. et al. Intracellular pathway of Onconase that enables its delivery to the cytosol. J Cell Sci 2007, 120(Pt. 8): 1405-11.
77. Costanzi, J., Sidransky, D., Navon, A. et al. Ribonucleases as a novel pro-apoptotic anticancer strategy: Review of the preclinical and clinical data for ranpirnase. Cancer Invest 2005, 23(7): 643-50.
78. Iordanov, M.S., Ryabinina, O.P., Wong, J. et al. Molecular determinants of apoptosis induced by the cytotoxic ribonuclease Onconase: Evidence for cytotoxic mechanisms different from inhibition of protein synthesis. Cancer Res 2000, 60(7): 1983-94.
79. Iwadate, Y., Fujimoto, S., Tagawa, M. et al. Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas. Int J Cancer 1996, 69(3): 236-40.
80. Gao, C.F., Ren, S., Zhang, L. et al. Caspase-dependent cytosolic release of cytochrome c and membrane translocation of Bax in p53-induced apoptosis. Exp Cell Res 2001, 265(1): 145-51.
81. Halicka, H.D., Murakami, T., Papageorgio, C.N. et al. Induction of differentiation of leukaemia (HL-60) or prostate cancer (LNCaP, JCA-1) cells potentiates apoptosis triggered by Onconase. Cell Prolif 2000, 33(6): 407-17.
82. Lee, I., Lee, Y.H., Mikulski, S.M. et al. Tumoricidal effects of Onconase on various tumors. J Surg Oncol 2000, 73(3): 164-71.
83. Rybak, S.M., Pearson, J.W., Fogler, W.E. et al. Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with Onconase, an antitumor ribonuclease. J Natl Cancer Inst 1996, 88(11): 747-53.
84. Juan, G., Ardelt, B., Li, X. et al. G1 arrest of U937 cells by Onconase is associated with suppression of cyclin D3 expression, induction of p16INK4A, p21WAF/CIP1 and p27KIP and decreased pRb phosphorylation. Leukemia 1998, 8: 1241-8.
85. Newton, D.L., Hansen, H.J., Mikulski, S.M. et al. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: Potential for the treatment of non-Hodgkin lymphoma. Blood 2001, 97(2): 528-35.
86. Ramos-Nino, M.E., Vianale, G., Sabo-Attwood, T. et al. Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase. Mol Cancer Ther 2005, 4(5): 835-42.
87. Mikulski, S.M., Ardelt, W., Shogen, K. et al. Striking increase of survival of mice bearing M109 Madison carcinoma treated with a novel protein from amphibian embryos. J Natl Cancer Inst 1990, 82(2): 151-3.
88. Smith, M.R., Newton, D.L., Mikulski, S.M. et al. Cell cycle-related differences in susceptibility of NIH/3T3 cells to ribonucleases. Exp Cell Res 1999, 247(1): 220-32.
89. Mikulski, S.M., Viera, A., Darzynkiewicz, Z. et al. Synergism between a novel amphibian oocyte ribonuclease and lovastatin in inducing cytostatic and cytotoxic effects in human lung and pancreatic carcinoma cell lines. Br J Cancer 1992, 66(2): 304-10.
90. Mikulski, S.M., Viera, A., Ardelt, W. et al. Tamoxifen and trifluoroperazine (Stelazine) potentiate cytostatic/cytotoxic effects of P-30 protein, a novel protein possessing anti-tumor activity. Cell Tissue Kinet 1990, 23(3): 237-46.
91. Lee, I., Kalota, A., Gewirtz, A.M. et al. Antitumor efficacy of the cytotoxic RNase, ranpirnase, on A549 human lung cancer xenografts of nude mice. Anticancer Res 2007, 27(1A): 299-307.
92. Lee, I., Lee, Y.H., Mikulski, S.M. et al. Effect of ONCONASE +/- tamoxifen on ASPC-1 human pancreatic tumors in nude mice. Adv Exp Med Biol 2003, 530: 187-96.
93. Lee, I., Lee, Y.H., Mikulski, S.M. et al. Enhanced cellular radiation sensitivity of androgen-independent human prostate tumor cells by Onconase. Anticancer Res 2000, 20(2A): 1037-40.
94. Nitta, K., Oyama, F., Oyama, R. et al. Ribonuclease activity of sialic acid-binding lectin from Rana catesbeiana eggs. Glycobiology 1993, 3(1): 37-45.
95. Notomista, E., Cafaro, V., Fusiello, R. et al. Effective expression and purification of recombinant Onconase, an antitumor protein. FEBS Lett 1999, 463(3): 211-5.
96. Hursey, M., Newton, D.L., Hansen, H.J. et al. Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: A new generation of therapeutics. Leuk Lymphoma 2002, 43(5): 953-9.
97. Vasandani, V.M., Burris, J.A., Sung, C. Reversible nephrotoxicity of Onconase and effect of lysine pH on renal Onconase uptake. Cancer Chemother Pharmacol 1999, 44(2): 164-9.
98. Merlino, A., Mazzarella, L., Carannante, A. et al. The importance of dynamic effects on the enzyme activity: X-ray structure and molecular dynamics of Onconase mutants. J Biol Chem 2005, 280(18): 17953-60.
99. Kim, B.M., Kim, H., Raines, R.T. et al. Glycosylation of Onconase increases its conformational stability and toxicity for cancer cells. Biochem Biophys Res Commun 2004, 315(4): 976-83.
100. Iwama, M., Ogawa, Y., Sasaki, N. et al. Effect of modification of the carboxyl groups of the sialic acid binding lectin from bullfrog (Rana catesbeiana) oocyte on anti-tumor activity. Biol Pharm Bull 2001, 24(9): 978-81.
101. Ogawa, Y., Iwama, M., Ohgi, K. et al. Effect of replacing the aspartic acid/glutamic acid residues of bullfrog sialic acid binding lectin with asparagine/glutamine and arginine on the inhibition of cell proliferation in murine leukemia P388 cells. Biol Pharm Bull 2002, 25(6): 722-7.
102. Mikulski, S. Phase I human clinical trial of Onconase (P-30 protein) administered intravenously on a weekly schedule in cancer patients with solid tumors. Int J Oncol 1993, 3: 57-64.
103. Mikulski, S.M., Costanzi, J.J., Vogelzang, N.J. et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 2002, 20(1): 274-81.
104. Puccio, C. A new anticancer Rnase (Onconase): Clinical trial in patients (pts) with breast cancer (BC). Proc Am Soc Clin Oncol (ASCO) 1996, 15: Abst 242.
105. Vogelzang, N.J., Aklilu, M., Stadler, W.M. et al. A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer. Invest New Drugs 2001, 19(3): 255-60.
106. Mikulski, S. Relationship between response rate and median survial in patients with advanced nonsmall cell lung cancer: Comparison of ONCONASE with other cancer agents. Int J Oncol 1995, 6: 889-97.
107. Martin, P.D., Doscher, M.S., Edwards, B.F. The refined crystal structure of a fully active semisynthetic ribonuclease at 1.8-A resolution. J Biol Chem 1987, 262(33): 15930-8.
108. Mazzarella, L., Capasso, S., Demasi, D. et al. Bovine seminal ribonuclease: Structure at 1.9 A resolution. Acta Crystallogr D Biol Crystallogr 1993, 49(Pt. 4): 389-402.